4th Pediatric Infectious Diseases Conference

 
 
Home  Back   ISSN 0973 - 0958
 
DHA and Chronic Diseases
DHA and Chronic Diseases
DHA and Chronic Diseases
DHA and Chronic Diseases
Follow Us : Follow On Facebook Follow On Twitter Follow On Youtube
DHA in Children
DHA IN CHILDREN
DHA in Children
DOCOSAHEXAENOIC ACID (DHA) AND CHRONIC DISEASES
DHA and Chronic Diseases
DHA and Chronic Diseases
Share
DHA :
Linoleic acid (LA) is an omega – 6 fatty acid and alpha-linolenic acid (ALA) is an omega-3 fatty acid are essential fatty acids for normal growth and development These fatty acids cannot be synthesized in the human body and must be obtained from the diet. These fatty acids are converted into very long chain polyunsaturated fatty acids (LC-PUFAs) through a series of desaturases and elongases.(1) LA is converted to docosahexaenoic acid (DHA) in the body, however rate of conversion varies from 0.2% and 21%.(2) The PUFA are important constituents of phospholipids. Phospholipids has been shown to be associated with normal growth and development, as well as in the outcome of chronic diseases such as coronary heart disease (CHD), hypertension, cancer, arthritis, allergies and other autoimmune diseases, since both omega-6 and omega-3 PUFAs are processed to powerful promoters of eicosanoids such as prostaglandins and leukotrienes. (3)

There is mounting literature to indicate that DHA may be of considerable benefit in the development of, retarding the progress of, or helping manage a number of chronic disorders especially cardiovascular disease/outcomes and associated risk factors. (4)
Action of DHA(5) :
(1)  
Decreased production of prostaglandin E2 (PGE2) metabolites
(2)  
Decrease in thromboxane A2, a potent platelet aggregator and vasoconstrictor
(3)  
Decrease in leukotriene B4 formation, an inducer of inflammation and a powerful inducer of leukocyte chemotaxis and adherence
(4)  
Increase in thromboxane A3, a weak platelet aggregator and a weak vasoconstrictor
(5)  
Increase in prostacyclin PGI3, leading to an overall increase in total prostacyclin by increasing PGI3 without a decrease in PGI2. Both PGI2 and PGI3 are active vasodilators and inhibitors of platelet aggregation; and
(6)  
Increase in leukotriene B5, a weak inducer of inflammation and a weak chemotactic agent

Thus, DHA in high doses lowers cholesterol and has antithrombotic and anti-inflammatory properties. (1)
Educational Section
 
Disclaimer:
The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
 
copyright ©2011 website design & development by Levioza
Follow Us
Follow us on :
Folllow Us